Gutsinda Lymphoma nini ya B-cell ikwirakwira hakoreshejwe uburyo bwa Bioocus Dual CAR-T Therapy

Amavuriro y'umurwayi

Rodney, umuntu urwaye indwara ikomeye ukomoka mu mahanga, yasanze afite Diffuse Large B-Cell Lymphoma (DLBCL), ubwoko bukomeye bwa lymphoma itari Hodgkin. Ku myaka 68, yashatse uburyo bwo kuvura buhanitse nyuma y’uko uburyo busanzwe bwo kuvura butameze neza. Yoherejwe mu kigo cy’abafatanyabikorwa bacu mu bitaro bya Tianjin Cancer, Rodney yinjiye muri Bioocus's dual CAR-T therapy protocol ifite nimero P1549. Ubu buryo bwo kuvura bwibasira antigens za CD19 na CD20 ku turemangingo twa kanseri, butanga igitero cy’ingingo ebyiri kugira ngo bwongere imikorere no kugabanya ibyago byo kongera kurwara.

Urugendo rw'Ubuvuzi

Ubuvuzi bwa Rodney bwatangiye muri Nzeri 2025, buterwamo uturemangingo twa CAR-T twakozwe mu buryo bwo kugaragaza antigen ya chimeric kuri CD19 na CD20. Ubu buryo bwasabaga gukusanya icyitegererezo cy'amaraso ye yo mu maraso (PB), kuyatunganya kugira ngo hakorwe uturemangingo twa CAR-T twihariye, no gutanga dose ijyanye n'ibyo akeneye. Nyuma yo guterwa, iterambere rye ryakurikiranwe cyane binyuze mu gupima amaraso mu minsi y'ingenzi yo gukurikirana: Umunsi wa 4 (D4), Umunsi wa 7 (D7), n'Umunsi wa 10 (D10).

• D4 (Ku ya 12 Nzeri 2025):Isuzuma rya mbere ryagaragaje ko hari utunyangingo twa CAR-T duto, aho utunyangingo twa CD19+ CAR-T turi kuri 0.50% bya CD3+ T (agaciro kabyo ni 6.04 × 10^6/L) na CD20+ CAR-T turi kuri 0.41% (agaciro kabyo ni 4.96 × 10^6/L). Iki cyiciro cya mbere cyagaragaje ko habayeho gutera imbere.
• D7 (Ku ya 15 Nzeri 2025):Kwaguka kwihutishijwe, aho uturemangingo twa CD19+ CAR-T twazamutse tugera kuri 1.68% (agaciro kabyo: 1.40 × 10^7/L) na uturemangingo twa CD20+ CAR-T tugera kuri 1.63% (agaciro kabyo: 1.36 × 10^7/L), bigaragaza ko twazamutse cyane.
• D10 (Ku ya 18 Nzeri 2025):Kwaguka gukomeye kwagaragaye, aho uturemangingo twa CD19+ CAR-T twageze kuri 31.43% bya selile za CD3+ T (agaciro kabyo ni 3.13 × 10^8/L) na selile za CD20+ CAR-T kuri 32.74% (agaciro kabyo ni 3.26 × 10^8/L). Isesengura rya subset ryagaragaje ko uburinganire mu turemangingo twa CD4+ na CD8+ T, aho umubare wa selile za T muri rusange uri kuri 2.9 × 10^9/L, harimo na selile za CD3+ T 34.35%.

Mu gihe cyose cy’igenzura, imiterere y’ubudahangarwa bwa Rodney yagaragaje impinduka nziza, nko kwiyongera k’uturemangingo twa T (CD3 + CD8 + kuri 69.56%), bishimangira ubushobozi bw’ubuvuzi bwo gushishikariza ubudahangarwa bwe kurwanya lymphoma.

Ibisubizo by'indashyikirwa

Kugeza kuri D10, ukwiyongera gukomeye mu tunyangingo twa CAR-T—kwiyongera inshuro 500 mu mibare ntarengwa ugereranyije na D4—byagaragaje imbaraga z’ubuvuzi mu kurwanya ikibyimba. Uku kwiyongera kwihuta ni ikimenyetso cy’ubuvuzi bwa CAR-T bwagenze neza, akenshi bufitanye isano no koroherwa mu buryo bwimbitse kandi burambye ku barwayi ba DLBCL. Rodney yihanganiye ubwo buvuzi neza, nta ngorane zikomeye zagaragaye mu cyiciro cyo gukurikirana. Urubanza rwe rugaragaza uburyo bwa Bioocus bwo gukora CAR-T ebyiri, bwageze ku gipimo cyo hejuru cy’ubutabazi bwuzuye (CR) n’igipimo rusange cy’ubutabazi (ORR) mu itsinda ry’abarwayi ku isi.